Trial Profile
Repaglinide for adolescents with cystic fibrosis-related diabetes
Status:
Withdrawn prior to enrolment
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Repaglinide (Primary) ; Insulin
- Indications Diabetes mellitus
- Focus Therapeutic Use
- 14 Feb 2008 The expected completion date for this trial is now 1 Aug 2007.
- 16 Nov 2007 Status changed from initiated to discontinued (unable to recruit any patients).
- 01 Oct 2006 New trial record.